tiprankstipranks
Trending News
More News >
Fu Shek Financial Holdings Limited (HK:2263)
:2263
Hong Kong Market

Fu Shek Financial Holdings Limited (2263) AI Stock Analysis

Compare
0 Followers

Top Page

HK

Fu Shek Financial Holdings Limited

(2263)

Rating:68Neutral
Price Target:
Fu Shek Financial Holdings Limited displays strong financial health with excellent cash flow generation and stable balance sheet metrics, contributing positively to the score. However, technical analysis indicates mixed momentum, and the high P/E ratio suggests valuation concerns. The absence of earnings call data and dividend yield also tempers the overall attractiveness of the stock.

Fu Shek Financial Holdings Limited (2263) vs. iShares MSCI Hong Kong ETF (EWH)

Fu Shek Financial Holdings Limited Business Overview & Revenue Model

Company DescriptionFu Shek Financial Holdings Limited (2263) is a Hong Kong-based company primarily engaged in the provision of financial services. The company's core services include securities brokerage, margin financing, and investment advisory. Fu Shek Financial Holdings is dedicated to delivering comprehensive financial solutions to its clients, leveraging its expertise and market insights to support investment strategies across various asset classes.
How the Company Makes MoneyFu Shek Financial Holdings Limited generates revenue through multiple streams within its financial services operations. The primary source of income is from securities brokerage services, where the company earns commissions on trades executed on behalf of clients. Additionally, the company offers margin financing, providing loans to clients for purchasing securities, with interest charged on these loans contributing a significant portion of revenue. Investment advisory services also play a role in the company's earnings, as Fu Shek provides clients with strategic investment advice for a fee. These diverse revenue streams are supported by the company's ability to maintain robust client relationships and adapt to market conditions.

Fu Shek Financial Holdings Limited Financial Statement Overview

Summary
Fu Shek Financial Holdings Limited exhibits solid financial performance with strong revenue growth and effective cost management. The company's balance sheet is robust with low leverage and a high equity ratio, signifying stability. Cash flow metrics are particularly impressive, demonstrating excellent cash generation capabilities, which bolster financial flexibility. Despite these strengths, there's potential for improving profitability metrics like ROE and net profit margin.
Income Statement
72
Positive
The company shows a strong gross profit margin of 46% but a moderate net profit margin of 7.9% for 2024. Revenue growth is substantial at 22.2%, indicating positive sales momentum. However, EBIT margin is impressive at 47.5%, suggesting effective cost management. EBITDA margin is lower at 11.2%, highlighting potential non-operational costs that need attention.
Balance Sheet
78
Positive
The balance sheet displays financial stability with a low debt-to-equity ratio of 0.003, indicating minimal leverage risk. ROE is modest at 1.0%, suggesting room for improvement in shareholder returns. The equity ratio is solid at 65.3%, showing a strong capital structure with substantial equity backing.
Cash Flow
85
Very Positive
Cash flow analysis reveals strong free cash flow growth of 100.2%, indicating robust cash generation. The operating cash flow to net income ratio of 28.1 highlights efficient cash conversion from earnings. Free cash flow to net income ratio is exceptionally high at 2803%, reflecting substantial liquidity and cash reserves.
Breakdown
TTMMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income StatementTotal Revenue
40.86M45.15M36.94M38.03M39.19M61.50M
Gross Profit
40.86M20.77M28.89M25.40M27.27M51.65M
EBIT
-2.11M7.38M20.73M16.85M16.45M22.60M
EBITDA
6.82M5.05M22.28M18.68M18.34M24.39M
Net Income Common Stockholders
3.29M3.57M12.01M12.81M10.69M13.60M
Balance SheetCash, Cash Equivalents and Short-Term Investments
62.05M230.65M132.07M103.72M92.41M149.53M
Total Assets
345.23M544.68M519.85M550.51M538.33M497.75M
Total Debt
3.10M1.14M1.27M32.73M1.51M13.25M
Net Debt
-58.13M-229.51M-130.80M-71.00M-90.90M-136.28M
Total Liabilities
194.97M189.14M167.89M210.55M211.18M181.28M
Stockholders Equity
150.26M355.54M351.97M339.96M327.15M316.47M
Cash FlowFree Cash Flow
17.84M100.00M49.94M-16.03M-43.47M27.31M
Operating Cash Flow
18.07M100.24M50.05M-16.02M-43.41M27.37M
Investing Cash Flow
-452.00K-234.00K-105.00K-7.00K-63.00K-57.00K
Financing Cash Flow
-1.01M-1.42M-31.56M27.34M-13.65M91.99M

Fu Shek Financial Holdings Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.18
Price Trends
50DMA
0.17
Positive
100DMA
0.17
Positive
200DMA
0.17
Positive
Market Momentum
MACD
<0.01
Negative
RSI
62.02
Neutral
STOCH
61.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2263, the sentiment is Positive. The current price of 0.18 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.17, and above the 200-day MA of 0.17, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 62.02 is Neutral, neither overbought nor oversold. The STOCH value of 61.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2263.

Fu Shek Financial Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
$385.47B12.828.44%4.00%17.45%8.24%
68
Neutral
HK$184.00M55.760.92%31.76%-35.29%
66
Neutral
$74.80B39.406.14%1.44%7.63%-24.23%
64
Neutral
$12.67B9.747.58%17015.08%12.21%-6.96%
54
Neutral
HK$490.93M100.000.18%3.12%-4.20%-96.68%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2263
Fu Shek Financial Holdings Limited
0.18
<0.01
5.88%
HK:1461
ZHONGTAI FUTURES Company Limited Class H
0.48
-0.04
-7.69%
HK:1177
Sino Biopharmaceutical
4.06
1.24
43.87%
HK:6030
CITIC Securities Co
19.40
7.56
63.92%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.